L. Hutchinson

发表

High drug attrition rates—where are we going wrong?

L. Hutchinson, R. Kirk, 2011, Nature Reviews Clinical Oncology.

Predicting cancer's next move

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Targeted therapies: Glioma—it's all in the site occupancy

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Genetics: BRAF but not KRAS is prognostic in colon cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?

L. Hutchinson, 2004, Nature Clinical Practice Oncology.

The transition experience of Enrolled Nurses to a Bachelor of Nursing at an Australian university

L. Hutchinson, C. Mitchell, W. S. John, 2011, Contemporary nurse.

Screening: CT screening for lung cancer: winner confirmed

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: Panitumumab improves PFS in mCRC with wild-type KRAS

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Imaging: Novel MRI technique distinguishes between glioma and radiation necrosis

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Screening: NELSON shows less is more in lung cancer screening

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Gynaecological cancer: CLOVAR validates prognostic gene-expression signature

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Screening: Where does stool DNA testing FIT in the CRC screening menu?

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Screening: Reduced breast cancer mortality rates in Europe are not due to screening

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Prevention: MAPping out breast cancer chemoprevention

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Urological cancer: Radical lessons learnt from the prostate cancer PIVOT trial

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Prevention: Low-fat diet linked to decline in breast cancer mortality

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Skin cancer: Golden age of melanoma therapy

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Genetics: What do breast and bladder cancer have in common?

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Lenalidomide for multiple myeloma

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Medical oncology: T-cell infiltrate predicts long-term survival in CRC

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Breast cancer: Shielding the ovaries from chemotherapy in breast cancer

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Lung cancer: Squiring immunotherapy to CheckMate

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Melanoma: Improving durable responses with TILs

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Immunotherapy: Cul-TIL-vating uveal melanoma regression

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Immunotherapy: CRISPR unveils T-cell-resistance mechanisms in tumours

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Immunotherapy: Shining light on immune-based mechanisms

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Biomarkers: Aneuploidy and immune evasion — a biomarker of response

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Urological cancer: Genetic landscape studies of prostate cancer offer new clues

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Neuroendocrine cancer: Combining two radiopeptide therapies improves survival

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Colorectal cancer: A step closer to combating acquired resistance in CRC

L. Hutchinson, 2012, Nature Reviews Gastroenterology &Hepatology.

Gastrointestinal cancer: A step closer to combating acquired resistance in CRC

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Immunotherapy: CheckMate—has nivolumab beaten melanoma?

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Targeted therapies: Bevacizumab and chemotherapy do not increase the risk of VTEs

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Medical oncology: Vascular normalization predicts response to cediranib

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Genetics: Predictor for prostate cancer

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Chemotherapy: Final ACT for standard of care in anal cancer?

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: FOLFIRI plus cetuximab—preferred first-line treatment for mCRC

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: Less is more for surgical treatment of oesophageal cancer

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Sticks and Stones and Broken Bones: The Influence of Parental Verbal Abuse on Peer Related Victimization

David Mueller, L. Hutchinson, 2008 .

Biomarkers: CtDNA—identifying cancer before it is clinically detectable

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Lung cancer: MET-negative patients—eclipsing benefits

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Hematology: Early disease predictor for ALL relapse

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Drug therapy: A new standard for thyroid cancer?

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Haematological cancer: Turning the clock back on clonal evolution

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Breast cancer: Radiation risk in BRCA carriers

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Immunotherapy: Pembrolizumab—is the writing on the wall for cancer?

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Breast cancer: SLN surgery alone is best for node-negative breast cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Chemotherapy: Supplements—for better or worse?

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

SSP reliability for breast cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Dosage of colloidal bismuth subcitrate in duodenal ulcer healing and clearance of Campylobacter pylori

C. O'Morain, L. Hutchinson, C. Keane, 1990, Alimentary pharmacology & therapeutics.

Genetics: Defining driver mutations in the genomic landscape of breast cancer

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Targeted therapies: LUX-Lung trials—not all mutations are created equal

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Hematology: IKZF1 alterations convey poor prognosis in ALL

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Haematological cancer: PD-1 blockade: opening the door to attack

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Oncology trials—the elephant in the room

L. Hutchinson, R. Kirk, 2012, Nature Reviews Clinical Oncology.

Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai

Pan Pantziarka, David J. Waxman, Nicolas André, 2016, Ecancermedicalscience.

Breast cancer: Challenges, controversies, breakthroughs

L. Hutchinson, Lisa Hutchinson, 2010, Nature Reviews Clinical Oncology.

Pancreatic cancer: Disrupting the chemokine axis in PDAC

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Targeted therapies: Progress for KRAS mutant NSCLC

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Closing the controversies gap in prostate cancer?

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Patient profiling in breast cancer—is knowledge power?

L. Hutchinson, R. Kirk, M. Villanueva, 2011, Nature Reviews Clinical Oncology.

Surgery: Rotterdam Criteria is most important prognostic factor

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan

U. Ledzewicz, F. Berthold, N. André, 2014, Ecancermedicalscience.

Immunotherapy: Harmonizing the immune response with a cancer vaccine

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Liver cancer: Gut microbiota feeds obesity-induced liver cancer

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Hematology: Allo SCT offers hope as second-line therapy for CML

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Targeted therapies: New standard for relapsed ALL

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Creating connections: Strategies to improve adolescent boys’ access and engagement with school-based health services

L. Hutchinson, W. S. John, 2012, Contemporary nurse.

The European Union and personalised cancer medicine.

I. Tannock, J. Hickman, L. Meheus, 2021, European journal of cancer.

Hematology: Bortezomib enhances chemotherapy effects in ABC DLBCL

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Risk factors: Cachexia—skeletal muscle depletion is a prognostic factor

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Chemotherapy: Cisplatin more effective when given less often

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Conflict of Interest Disclosures

V. Devita, L. Hutchinson, Jessica J. Tilton, 2018, Global spine journal.

Breast cancer: BEATRICE bevacizumab trial—every cloud has a silver lining

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Genetics: Serpins' role in brain metastasis uncovered

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Pancreatic cancer: Vaccine is safe and improves survival

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Targeted therapies: Human CML stem cells insensitive to imatinib even when BCR–ABL is inhibited

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Tumour response, correlates of survival and clinical benefit

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Socialization or prisonization? Utilizing Sykes’ “pains of imprisonment” to examine deprivations in America’s public schools

L. Hutchinson, W. E. Pullman, 2007 .

Breast cancer: Anastrozole sets the STAGE for premenopausal women

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

The era of personalized medicine: back to basics

V. Devita, L. Hutchinson, 2008, Nature Clinical Practice Oncology.

Targeted therapies: Another option for metastatic RCC

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Targeted therapies: Benefit shown from continued adjuvant trastuzumab tHERApy

L. Hutchinson, 2011, Nature Reviews Clinical Oncology.

Imaging: Digital infrared breast scan shows promise for detecting cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Personalized cancer medicine: era of promise and progress

L. Hutchinson, Lisa Hutchinson, 2011, Nature Reviews Clinical Oncology.

Immunotherapy: CAR-modified T cells targeting CD19—curing the incurable

L. Hutchinson, 2014, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: CROSS: new standard of care for oesophageal cancer

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Palliative care: Analgesia prescribing in the USA—no gain, much pain

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Melanoma: JAK — opening the door to acquired resistance

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Immunotherapy: Relapse—tuning the microenvironment

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Haematological cancer: PROLONGing PFS with ofatumumab in patients with CLL

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Immunotherapy: Evading immune escape: synergy of COX and immune-checkpoint inhibitors

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Haematological cancer: Less is more for paediatric patients—it's ALL in the dosing

L. Hutchinson, 2012, Nature Reviews Clinical Oncology.

Herceptin: HERalding a new era in breast cancer care but at what cost?

V. Devita, L. Hutchinson, 2005, Nature Clinical Practice Oncology.

Targeted therapies: Selumetinib MEKing differences in NF1

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Radiotherapy: Abscopal responses: pro-immunogenic effects of radiotherapy

L. Hutchinson, 2015, Nature Reviews Clinical Oncology.

Gefitinib efficacy in adenocarcinoma

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.

Ovarian cancer: FAK — new target for antiangiogenic therapy

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Lung cancer: AURA3 magic reveals new standard

L. Hutchinson, 2017, Nature Reviews Clinical Oncology.

Lung cancer: OPTIMAL results for erlotinib in NSCLC

L. Hutchinson, 2013, Nature Reviews Clinical Oncology.

Immunotherapy: Robust responses to intraperitoneal IL-2 in ovarian cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

The transition experience of Enrolled Nurses to a Bachelor of Nursing at an Australian university

L. Hutchinson, C. Mitchell, W. S. John, 2011, Contemporary nurse.

Haematological cancers: Lenalidomide — SPRINT to a new standard?

L. Hutchinson, 2016, Nature Reviews Clinical Oncology.

Hematology: Nilotinib as first-line therapy for Ph+ CML

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Diagnosis: Gene-expression signature in urine diagnoses aggressive bladder cancer

L. Hutchinson, 2010, Nature Reviews Clinical Oncology.

Bladder cancer: Gene-expression signature in urine indicates aggressive disease

L. Hutchinson, 2010, Nature Reviews Urology.

Clinical pharmacology: CYP2D6 polymorphisms associated with tamoxifen outcome

L. Hutchinson, 2009, Nature Reviews Clinical Oncology.